As a post-doctoral fellow, Dr. Dyke developed the first technique at Memorial Sloan Kettering Cancer Center (MSKCC) to non-invasively assess the grade of neoadjuvant chemotherapy in pediatric subjects with osteogenic or Ewing’s sarcomas using dynamic contrast enhanced (DCE)-MRI. This technique is still in use and lets the orthopedic surgeon determine tumor response to chemotherapy prior to surgical resection. Receiver operator characteristics provided optimal DCE-MRI cutoffs to assess varying tumor grades. An additional paper from his group validated DCE-MRI contrast uptake with the histologically determined degree of vascular endothelial growth factor (VEGF) in excised tumor.
Related Publications: (1) Dyke J.P., et al., Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging, Radiology: 2003;228:271-278. (2) Hoang B.H., et al., VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI, Clin. Orthop.: 2004;426:32-38.
Associated Institute: MSKCC